Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States-Reference-Cited by-同舟云学术

Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States

Author:

Stevenson James M.¹,Alexander G. Caleb²³⁴,Palamuttam Natasha⁵,Mehta Hemalkumar B.²³

Affiliation:

1. Division of Clinical Pharmacology Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Center for Drug Safety and Effectiveness Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

3. Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

4. Division of General Internal Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

5. Division of Health Sciences Informatics Johns Hopkins University School of Medicine Baltimore Maryland USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

Reference50 articles.

1. United States Food and Drug Administration.Table of pharmacogenomic biomarkers in drug labeling (2020). Accessed May 5 2020.

5. Centers for Disease Control and Prevention.COVIDView: A Weekly Surveillance Summary of U.S. COVID‐19 Activity (2020). Accessed September 30 2020.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献